Imagine a damaged nerve as a broken electrical cable. Instead of just hoping the wires reconnect, this technology provides a protective, biocompatible tube made from silk proteins that guides the nerve back together. It acts like a temporary scaffold that prevents scarring and protects the area while the body heals itself.
Current peripheral nerve repair methods fail 50% of the time, leaving 30% of patients with permanent disabilities and creating a massive socio-economic burden.
SILKBridge, a silk fibroin-based nerve guide. The project also established an ISO 13485 compliant quality management system and automated manufacturing steps.
If you are a surgical implant manufacturer dealing with high failure rates in nerve repair—this project developed SILKBridge, a silk fibroin guide that reduces the 50% unsuccessful repair rate. It provides a cost-effective, off-the-shelf alternative to autografts.
If you are a clinic network dealing with long patient recovery times and high rehabilitation costs—this project developed a nerve guide that reduces fibrosis and immune rejection. This allows for faster healing and lower long-term care costs for the 4 million people injured annually.
If you are a biomaterials company dealing with the need for scalable, biocompatible scaffolds—this project developed an automated manufacturing process for silk fibroin fibers. It demonstrates a path to ISO 13485 certified production of nerve conduits.
The project describes SILKBridge as a cost-effective nerve guide that reduces the overall socio-economic burden by lowering rehabilitation costs and the need for prolonged surgeries.
Yes, the project has focused on scaling up manufacturing processes and initiating automation strategies to move toward market readiness.
Based on available project data, the technology is developed by KLISBIO SRL, but specific patent or licensing terms are not detailed in the summary.
The project has developed a quality management system in line with ISO 13485 to ensure regulatory compliance and market readiness.
The project runs from July 2024 to June 2026, with current efforts focused on refining design and preparing for clinical trials.
The project is led by a single Italian SME, KLISBIO SRL, with a 100% industry ratio. This lean structure suggests a highly focused commercial drive, as the company is directly managing the transition from a first-in-human study to industrial scale-up and ISO certification without relying on academic partners for the current phase.
Contact KLISBIO SRL in Italy for licensing or partnership inquiries.
Contact us to explore partnership opportunities with KLISBIO SRL.
